Immunology
Global

Immunology Experts

Steven C. Gilman, Ph.d.

MD
immunology
Technical University of Denmark
Angola

Biography

Dr. Gilman joined the Board in April 2016 and brings more than 28 years of scientific and development expertise in the healthcare industry. Dr. Gilman served most recently as chief scientific officer of Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist, he served as chairman of the Board of Directors and chief executive officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including vice president and general manager of Inflammation. Prior to Millennium, he was group director at Pfizer Global Research and Development, where he was responsible for drug discovery of several therapeutic areas, including immunology and antibacterials. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College. He currently serves as Chairman and  CEO of ContraFect Corporation (Nasdaq:CFRX) and on the board of directors of Vericel (Nasdaq:VCEL), SCYNEXIS (Nasdaq:SCYX), the Massachusetts Biotechnology Association, the Northeastern University Drug Discovery Advisory Board and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his M.S. and Ph.D. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.  

Research Interest

Dr. Gilman joined the Board in April 2016 and brings more than 28 years of scientific and development expertise in the healthcare industry. Dr. Gilman served most recently as chief scientific officer of Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist, he served as chairman of the Board of Directors and chief executive officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including vice president and general manager of Inflammation. Prior to Millennium, he was group director at Pfizer Global Research and Development, where he was responsible for drug discovery of several therapeutic areas, including immunology and antibacterials. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College. He currently serves as Chairman and  CEO of ContraFect Corporation (Nasdaq:CFRX) and on the board of directors of Vericel (Nasdaq:VCEL), SCYNEXIS (Nasdaq:SCYX), the Massachusetts Biotechnology Association, the Northeastern University Drug Discovery Advisory Board and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his M.S. and Ph.D. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.  

Global Experts from Angola

Global Experts in Subject

Share This Profile
Recommended Conferences
  • 3rd International Conference on Autoimmunity

    November 26-27, 2018 Dublin, UK

  •  Theme: Novel Research and Therapeutic Challenges in Antibodies and Antibiotics

    December 05-06, 2018 Chicago, USA

  • 4th Antibodies, Antibiotics and Bio Therapeutics Congress

    December 05-06, 2018 Chicago, USA

  • 13th International Conference on Allergy and Clinical Immunology

    December 13-14 , 2018 Abu Dhabi, UAE

View more
Relevant Topics